Furthermore, high mutation rate of EGFR in East Asian populations together with the inert tumor immune microenvironment in lesions presenting as pGGN collectively implied a heterogeneous and limited response to immunotherapy in patients with MPLC [30]. This evidence concerns the gene EGFR and neoplasm.